Clinical Scorecard: A predictive nomogram combining DCE-MRI imaging characteristics and clinicopathological factors for assessing pathological complete response in HER2-positive breast cancer

At a Glance

Key Highlights

• Overall pathological complete response (pCR) rate was 44.6% in the study cohort.
• Independent predictors of pCR included ADCmin value, Ki-67 index, tumor size, clinical N stage, and HR status.
• The nomogram demonstrated excellent discrimination with AUC of 0.823 in the training cohort and 0.795 in the validation cohort.
• Molecular subtype analysis showed higher pCR rates in HR-/HER2+ patients compared to HR+/HER2+ patients.
• Integration of imaging biomarkers with clinicopathological variables may enhance prediction accuracy.

Guideline-Based Recommendations

Diagnosis

• HER2-positive status defined as immunohistochemistry 3+ or FISH amplification ratio ≥2.0.

Management

• Neoadjuvant chemotherapy combined with anti-HER2 targeted agents is standard treatment.

Monitoring & Follow-up

• Pathological complete response (pCR) serves as a prognostic indicator for long-term survival outcomes.

Risks

• Approximately 40-60% of patients may not achieve pCR despite treatment.

Patient & Prescribing Data

HER2-positive breast cancer patients receiving neoadjuvant chemotherapy.

Integration of DCE-MRI imaging features with clinical parameters may inform treatment decisions.

Clinical Best Practices

• Utilize nomograms for prognostic stratification and clinical decision support in HER2-positive breast cancer.
• Incorporate multi-omics profiling and imaging data for individualized treatment planning.

Related Resources & Content

• Study on HER2-positive breast cancer